Myelodysplasia: When to treat and how

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 2, 2006, Pages 293-300

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Azacitidine; Decitabine; Lenalidomide; Myelodysplasia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ANGIOGENESIS INHIBITOR; AZACITIDINE; BEVACIZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LENALIDOMIDE; LONAFARNIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; TLK 199; VALPROIC ACID; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CLINICAL TRIAL; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; INFECTION RISK; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCYTOPENIA; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REMISSION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ANEMIA; ANGIOGENESIS INHIBITORS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33644498884     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.11.005     Document Type: Review

References (15)

1. Y. Saunthararajah R. Nakamura R. Wesley et. al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 2003 3025-3027
2. F. Landi G. Onder M. Cesari et. al. Effects of influenza vaccination on mortality among frail, community-living elderly patients: An observational study Aging Clin Exp Res 15 2003 254-258
3. P. Venugopal S. Manson H.D. Preisler Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias Cancer Treat Res 108 2001 257-265
4. P. Greenberg C. Cox M.M. LeBeau et. al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
5. L.R. Silverman J.F. Holland R.S. Weinberg et. al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 7 supplement 1 1993 21-29
6. L.R. Silverman J.F. Holland E.A. Demakos Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921 Ann Hematol 68 1994 A12 [abstr]
7. L.R. Silverman E.P. Demakos B.L. Peterson et. al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B J Clin Oncol 20 2002 2429-2440
8. A.B. Kornblith J.E. Herndon L.R. Silverman et. al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study J Clin Oncol 20 2002 2441-2452
9. H. Saba C. Rosenfeld J.-P. Issa et. al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS) Blood 104 2004 23a [abstr]
10. 2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules Blood 104 2004 402a [abstr]
11. A. List S. Kurtin D.J. Roe et. al. Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549-557
12. A.F. List G. Dewald J. Bennett et. al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study J Clin Oncol 23 2005 2s [abstr]
13. Hugin RJ, Gill BP of Celgene Corporation. Preliminary Clinical Data presented on Revlimid (TM) in Malignant Blood Disorders, December 5, 2004, http://ir.celgene.com/phoenix.zhtml?c=111960&p= irol-newsArticle&ID=650409&highlight=., http://ir.celgene.com/phoenix.zhtml?c=111960&p= irol-newsArticle&ID=650409&highlight=
14. H.J. Deeg H.M. Shulman J.E. Anderson et. al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55-66 years of age Blood 95 2000 1188-1194
15. H. Castro-Malaspina R.E. Harris J. Gajewski et. al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program Blood 99 2002 1943-1951